On October 10, 2024, the MaRS Discovery District in Toronto was abuzz with excitement as over 200 life science industry leaders, investors, and researchers gathered for the inaugural UHNLeashed Commercialization & Partnering Showcase. Hosted by Commercialization at UHN, this event showcased cutting-edge biomedical innovations and fostered meaningful partnerships aimed at transforming game-changing research into real-world medical solutions.
The showcase featured a day packed with inspiring keynote presentations, dynamic breakout sessions, and a thought-provoking panel on harnessing the power of AI and data in health care. Speakers delved into the potential of artificial intelligence, digital health, and imaging technologies to revolutionize patient care, demonstrating UHN's role at the forefront of global medical innovation.
A key highlight of the event was the public launch of UHN's Accelerator Fund, a philanthropic initiative jointly supported by the UHN Foundation and Princess Margaret Cancer Foundation, designed to bridge the funding gap in early-stage commercialization. Drs. Sarah Crome, Pamela Ohashi, and Shin Ogawa, the first recipients of the Accelerator Fund, shared their promising research and outlined how the fund would help drive their discoveries closer to clinical impact. This initiative is a testament to UHN’s dedication to supporting high-potential research and ensuring that breakthrough technologies make it to the patients who need them most.
Throughout the day, participants were treated to a series of presentations from UHN companies and new ventures, exploring investment-ready life sciences opportunities, as well as UHN's vast resources for product development partnerships. A key feature was the Partnering Café, which encouraged direct networking between researchers, investors, and industry professionals—an essential space for building partnerships to advance UHN’s health care innovations.
With its exceptional infrastructure, world-class researchers, and strong ties to industry and philanthropic partners, UHN is leading the charge in turning tomorrow’s medical breakthroughs into today’s therapies, impacting patients across Canada and around the globe.
UHNLeashed was not just an event—it was a catalyst for change, setting the stage for powerful collaborations that will drive the future of health care forward.
For a closer look at the event’s highlights, visit UHNLeashed Highlights.
“The human genome is highly complex. Every cell in our body has 6 billion letters of DNA, but only 1.5% are found in genes. The vast majority of DNA letters are found in ‘non-coding elements’ of our genome, controlling how genes are used differently across a variety of cell types in our body,” says Dr. Mathieu Lupien, recently elected Fellow of the Royal Society of Canada for his cancer epigenetics research and Chair of Genetics & Epigenetics Program at Princess Margaret Cancer Centre (PM).
To fully understand the complexity of the genome, epigenetics cannot be overlooked. Simply put, epigenetics involves the additional information on top of DNA that guides each cell in our body to use its copy of the human genome in unique ways.
“Cells can accumulate variations in the epigenetic layer, called chromatin variants, that fine-tune cell identity within an individual,” Mathieu explains.
Chromatin is the structure that packages DNA in the cell nucleus. It consists of DNA wrapped around histone proteins, forming nucleosomes. Think of chromatin like a bookshelf where the DNA is stored. Just like how tightly or loosely books are arranged can affect how easily you can access them, the structure of chromatin affects whether genes are ‘open’ or ‘closed’ to the cell’s reading machinery.When DNA is accessible in one cell type but not in another due to differences in chromatin compaction, this phenomenon is referred to as chromatin variants.
Most chromatin variants affect the non-coding regions of the genome, which harbours all the information to fine tune gene expression across each cell type in the human body. For instance, the non-coding regions include promoters, which are DNA sequences upstream of genes, act like light switches to turn genes “on” for expression. Enhancers are another example of non-coding regions found far from genes, that function like light dimmers, coordinating with promoters to adjust gene expression levels. However, how chromatin variants impact these regions of the genome to favour cancer development remains a largely unexplored and mysterious area.
DNA organization inside the cell.
Cancer can arise when chromatin variants accumulate, disrupting normal gene function and promoting uncontrolled cell growth. From Mathieu’s earliest study published in Cell, the team was the first to identify a type of chromatin variant that causes a DNA reading protein, FoxA1, to contribute to both breast cancer and prostate cancer development.
FoxA1 can recognize distinct stretches of DNA because of this type of chromatin variation, present in both cancer types. Those stretches were identified to be enhancers that regulate the gene expression specific to either breast or prostate cancer.
Mathieu moved his lab to PM in 2012 to tap into the local expertise in cancer stem cells. He collaborated with Dr. John Dick and Dr. Peter Dirks to use epigenetics to explore the underlying mechanisms of cancer renewal properties. Since then, he contributed to systematically indexing the genome of normal and cancer cells to build an encyclopedia of non-coding DNA elements across the human genome to unveil cancer-associated epigenetic variation in diverse cancer types, including blood, brain, prostate, breast and colon cancers.
“There has been a research focus on genetic mutations as a cause of cancer,” says Mathieu. “But more and more evidence is also showing how cancer can be a disease of the chromatin.”
Chromatin variant in pediatric ependymoma
Collaborating with Dr. Michael Taylor at SickKids, Mathieu’s team helped identify the first instance of a cancer type, pediatric ependymoma, arising from chromatin variants independently of genetic mutations.
Ependymoma is a type of cancer found in the nervous system and it is more frequently diagnosed in children than in adulthood. With fewer years to be exposed to carcinogens, children accumulate fewer mutations in their tumours compared to adult cancers, making it a puzzling case to understand their origins.
Tapping into the expertise of a team of epigenetics scientists including Mathieu, pediatric ependymomas were found in a study to stratify into two groups based on chromatin variants, revealing clear variations in epigenetics. Further investigation linked these patterns to environmental factors and prompted a clinical trial to test the effectiveness of epigenetic therapy, a new class of treatment options targeting chromatin variants.
Chromatin variant in triple-negative breast cancer
Studying the therapeutic resistance in breast cancer, Mathieu’s team discovered a new class of chromatin variants in chemo-resistant cancer cells, suggesting that this particular class might be treatable with epigenetic therapy.
Together with Dr. Cheryl Arrowsmith and the Structural Genomics Consortium, the team tested a series of chemical compounds in preclinical settings and showed that a specific subset of these compounds can inhibit tumour growth. Mathieu now collaborates with Dr. David Cescon, a Medical Oncologist and Clinician Scientist at PM, to determine the best way to bring epigenetic therapy into the clinic.
Mathieu was named Allan Slaight Collaborator of the Year in 2022 and has made significant strides in the field of epigenetics through his collaborative efforts.
“Collaboration is the primary source for innovation,” says Mathieu. “We innovate by merging different fields together. And by collaborating with field experts, we can avoid going blindly into a new space.”
Mathieu emphasizes the importance of strategic collaboration in academia. “Before collaborations, one needs to establish their own value proposition clearly—what you’re good at and where you need complementary expertise to accomplish what you want. Then you can engage in fruitful collaborations.”
Looking to the future, Mathieu is optimistic about the integration of epigenetics into clinical practice. “What I look forward to in the future is for the field of epigenetics to be embedded within clinical practice. Today, I’m a researcher but I am also the friend, the relative of a cancer patient. I hope that the discoveries my team is making today can inform of a new era of clinical practices.”
“It’s heading in the right direction, and hopefully, we’ll see epigenetic research transform the clinic soon.”
Meet PMResearch is a story series that features Princess Margaret researchers. It showcases the research of world-class scientists, as well as their passions and interests in career and life—from hobbies and avocations to career trajectories and life philosophies. The researchers that we select are relevant to advocacy/awareness initiatives or have recently received awards or published papers. We are also showcasing the diversity of our staff in keeping with UHN themes and priorities.
A recent breakthrough from McEwen Stem Cell Institute has uncovered a key player in pancreatic development: immune cells known as macrophages. These cells were found to play a supportive role in the growth and development of insulin-producing beta-like cells in the pancreas.
The pancreas aids in digestion and releases hormones that regulate blood sugar. However, human pancreas development is highly complex, and little is known about how certain cell populations, including immune cells, contribute to this process. This is crucial because improper immune cell function during pancreatic fetal growth may lead to autoimmune diseases like type 1 diabetes.
While previous evidence suggests that macrophages are important for organ formation, studying this in the human pancreas has been particularly challenging.
In this study, researchers examined the developing pancreas using cutting-edge RNA sequencing techniques. They discovered a variety of hematopoietic (blood forming) cells, including two distinct types of macrophages that appear to be specifically associated with fetal pancreas development.
To explore these findings further, the team created a model using stem cells to grow mini, pancreatic-islet-like structures called organoids. These organoids contained both endocrine (hormone releasing) cells and macrophages, allowing scientists to study their interactions closely.
The results were striking—macrophages helped support the differentiation and survival of the endocrine cells and beta-like cells in particular. Additionally, when the organoids were transplanted into tissue, the presence of macrophages aided the success of the transplant.
These findings suggest that macrophages may be key players in the development of pancreatic endocrine cells, opening new doors for understanding and treating diabetes. By harnessing the power of macrophages, researchers could develop more effective strategies for engineering pancreatic tissue, offering hope for future diabetes therapies.
The first author of this study is Dr. Adriana Migliorini, Scientific Associate at McEwen Stem Cell Institute.
The senior author of this study is Dr. Cristina Nostro, Senior Scientist at McEwen Stem Cell Institute and Associate Professor in the Department of Physiology at the University of Toronto.
This work was supported by the Ontario Institute for Regenerative Medicine, the Howard Webster Foundation, the Canadian Foundation for Innovation and Ontario Research Fund, Breakthrough Type 1 Diabetes International, Canadian Institutes of Health Research, the Banting and Best Diabetes Centre, Canadian Islet Research and Training Network, Medicine by Design, Canada First Research Excellence Fund, and UHN Foundation.
Dr. Adriana Migliorini, Dr. Gordon M. Keller, Dr. Michael H. Atkins, and Dr. Cristina Nostro are co-inventors of one patent application related to this work. Dr. Cristina Nostro also has a patent licensed to Sernova Inc.
Migliorini A, Ge S, Atkins MH, Oakie A, Sambathkumar R, Kent G, Huang H, Sing A, Chua C, Gehring AJ, Keller GM, Notta F, Nostro MC. Embryonic macrophages support endocrine commitment during human pancreatic differentiation. Cell Stem Cell. 2024 Oct 10:S1934-5909(24)00325-4. doi: 10.1016/j.stem.2024.09.011. Epub ahead of print.
Every year, over 650 internationally trained clinical fellows come to UHN to advance their clinical skills and contribute their expertise to Canadian health care. However, starting medical training in a new country is often overwhelming, especially for international clinical fellows who must adjust to different health care systems, cultural norms, and communication styles.
To tackle these challenges, researchers at The Institute for Education Research at UHN developed ‘Transitions’—a specialized program designed to help internationally trained clinical fellows adapt smoothly to medical training in Canada.
The Transitions program offers a flexible blend of online modules with live virtual sessions. It covers critical topics such as navigating the Canadian health care system, effective communication, patient safety, medical ethics, and social determinants of health.
In the pilot program, 65 fellows from 11 different medical specialties participated. They reported improved learning experiences, reduced anxiety, increased confidence and a stronger sense of community with their peers.
“The success of this pilot demonstrates that tailored support can make a meaningful difference,” adds Dr. Ahmed Al-Awamer, lead author of the study and Educational Investigator at The Institute for Education Research at UHN. “This program isn’t just a bridge; it equips internationally trained clinicians with the confidence and connections they need to make an immediate impact in Canadian health care.”
Transitions is not only flexible and practical but also cost-effective, making it a solution that can be easily adopted by other institutions to support medical trainees from around the world. This year, the Transitions program has expanded and accepted around 300 international clinical fellows. The team seeks to continue improving and expanding this program.
Dr. Ahmed Al-Awamer is the lead author of the study and an Educational Investigator at The Institute for Education Research at UHN. Dr. Al-Awamer is also an Associate Professor in the Department of Family and Community Medicine at the University of Toronto (U of T) and a Scholar at The Wilson Centre for Research Education at UHN and U of T.
This work was supported by UHN Foundation, UHN International Centre of Education, and UHN Clinical Education.
Al-Awamer A, Malavade T, Jardine J, Kaya E. 'Transitions': A new pilot programme to support the transitions of new internationally educated clinical fellows. Med Educ. 2024 Nov. doi: 10.1111/medu.15523.
Breast Cancer Awareness Month is an opportunity to highlight both the strides made in research and the ongoing commitment to shape the future of breast cancer treatment and care.
At Princess Margaret Cancer Centre, Senior Scientist and Surgeon, Dr. Michael Reedijk is developing more effective treatments for triple-negative breast cancer (TNBC), a particularly aggressive form of the disease.
Unlike other types of breast cancer, TNBC lacks the receptors that most targeted therapies rely on, making it harder to treat.
“Triple-negative breast cancer accounts for 15-20% of breast cancer cases but has double the mortality rate of the other types, underscoring the tremendous need for targeted therapies.” Says Dr. Reedijk. “There is a great deal of effort going into finding these targeted therapies and that is my lab’s main focus. We aim to uncover drivers and specific characteristics of triple-negative breast cancer.”
One promising avenue of research is immunotherapy, which uses the body's own immune system to attack cancer cells. While this approach has been highly successful in treating some cancers, it has been less effective in TNBC. To improve these outcomes, Dr. Reedijk’s lab is investigating how TNBC interacts with the immune system.
In a recent study, Dr. Reedijk’s lab identified a potential new therapeutic approach that could enhance the treatment efficacy of immunotherapy for TNBC.
TNBC tumours are often heavily infiltrated by immune cells, a unique trait compared to other types of breast cancers. The presence of specific immune cells can impact patient survival: high levels of tumour-associated macrophages (TAMs) are linked to worse outcomes, while increased cytotoxic T cells (CTLs) are associated with better survival. However, the mechanisms that regulate this are poorly understood.
“Immune checkpoint inhibitors—drugs that prevent cancer from evading the immune system—have shown mixed results for TNBC and this is in part because TAMs can block that immune response against cancer cells,” explains Dr. Reedijk. “We are exploring TAMs as a therapeutic target by investigating the molecular mechanisms underlying how they are regulated.”
Dr. Reedijk’s lab previously found that TNBC tumours produce IL1β, a protein that attracts TAMs and reduces CTLs, promoting cancer growth. His team, including first authors Dr. Weiyue Zheng, a Scientific Associate in Dr. Reedjik’s lab and Dr. Wanda Marini, a medical resident at the University of Toronto, sought to investigate this further.
Using pre-clinical models, they found that a protein involved in producing IL1β, called caspase-1, is specifically increased in TNBC and that blocking this protein reduces TAM levels and increases the tumour’s response to immunotherapy.
This study uncovers a key mechanism behind TNCB’s response to immunotherapy and offers a promising target for future treatments. These findings are being explored in patients with TNBC in a phase 1 clinical trial set to open in November, 2024.
To learn more about Dr. Reedijk’s work, see the video below.
Dr. Reedijk’s lab has recently published additional work on improving immunotherapy in TNBC through regulation of the Notch signaling pathway—a key developmental pathway that is abnormal in TNBC. To read about this research, click here.
This work was supported by the Canadian Cancer Society, the Canadian Institute of Health Research, the Ontario Ministry of Health and Long-Term Care, The Princess Margaret Cancer Foundation and funding from S. Qureshi and family.
Dr. Michael Reedijk is an Associate Professor of Surgery at the University of Toronto.
Zheng W, Marini W, Murakami K, Sotov V, Butler M, Gorrini C, Ohashi PS, Reedijk M. Caspase-1-dependent spatiality in triple-negative breast cancer and response to immunotherapy. Nat Commun. 2024 Oct 1;15(1):8514. doi: 10.1038/s41467-024-52553-6.
A recent study from UHN’s Krembil Brain Institute has revealed important differences in brain activity between Parkinson disease and dystonia, two movement disorders with contrasting symptoms. Parkinson usually causes slow or reduced movement, while dystonia makes muscles contract uncontrollably.
Parkinson and dystonia are both tied to problems in the brain’s movement control systems, specifically in the basal ganglia. These issues involve certain pathways to a specific region called the globus pallidus internus (GPi). In Parkinson, nerve cells in the GPi become more active, while in dystonia, these cells fire less often.
Even though the brain circuits act differently in Parkinson and dystonia, doctors use the same treatment—deep brain stimulation (DBS)—to manage movement symptoms in both conditions. DBS involves placing tiny electrodes in specific parts of the brain to help regulate abnormal brain activity. Still, patients with each disorder respond differently, suggesting disease-specific changes in brain connections.
To investigate this further, researchers studied the brain activity of GPi neurons in patients undergoing DBS treatment. They found that in dystonia, nerve cells fired more slowly, irregularly, and often in bursts, compared to in Parkinson disease. In addition, the researchers discovered that certain brain wave patterns—theta waves in dystonia and low-beta waves in Parkinson—are directly related to the severity of movement symptoms in each condition. This provides single-cell resolution support of earlier studies that found similar connections between these frequency patterns and symptoms in people with Parkinson and dystonia.
The researchers also examined how the brain changes after electrical stimulation, a process called brain plasticity. They found that this process works differently in Parkinson disease and dystonia. In dystonia, the brain seems to be less capable of long-term changes, meaning its wiring is less flexible compared to Parkinson disease.
These findings not only offer a deeper understanding of the differences between Parkinson and dystonia at a cellular level, but can also help to improve treatments like deep brain stimulation by tailoring approaches to each disorder’s specific brain activity patterns and responses to electrical stimulation.
The first authors of this study are Srdjan Sumarac, Doctoral Candidate at Krembil Research Institute, Kiah A. Spencer, Doctoral Candidate, and Dr. Leon A. Steiner, Postdoctoral Researcher at Krembil Research Institute and Universitätsmedizin Berlin.
The senior author of this study is Dr. Luka Milosevic, Scientist at Krembil Research Institute, Affiliate Scientist at KITE Research Institute, and Assistant Professor at the University of Toronto.
This work was supported by Brain Canada in partnership with the Azrieli Foundation, the Banting Research Foundation in partnership with the Dystonia Medical Research Foundation, and UHN Foundation.
Sumarac S, Spencer KA, Steiner LA, Fearon C, Haniff EA, Kühn AA, Hodaie M, Kalia SK, Lozano A, Fasano A, Hutchison WD, Milosevic L. Interrogating basal ganglia circuit function in people with Parkinson's disease and dystonia. Elife. 2024 Aug 27;12:RP90454. doi: 10.7554/eLife.90454.
Canada’s health care system faces significant challenges, with millions experiencing inequities in care and lacking access to essential services. Addressing these challenges requires bold innovation in health care education—empowering health professional students with knowledge and the tools to lead transformative change.
Students have the potential to lead change, but they are often seen as passive learners rather than active participants in change. In a recent article published by Dr. Kathryn Parker, Educational Investigator at The Institute for Education Research, researchers highlight the value of transformative education, which places students at the forefront and teaches them to challenge inequities, question existing systems, and engage in compassionate leadership.
Student-led Learning Environments* (SLEs) are a new way of teaching that offers unique, real-world experiences that bring together students, patients, families, and other health care professionals to create solutions to pressing health care gaps.
Recently, 79 students from 12 different health care professions collaborated in SLEs, dedicating over 8,000 hours to learning, leadership, and service and impacting over 3,000 patients. These programs give students practical, hands-on training and also empower them to help create equitable and compassionate care models. By fostering collaboration, critical thinking, and leadership, SLEs are transforming health care education—and, in turn, health care itself.
This work was supported by UHN Foundation, Employment and Social Development Canada through the Foundation for Advancing Family Medicine, the College of Family Physicians of Canada, and the Canadian Health Workforce Network. Kathryn Parker is an Associate Professor of Transformative Change at the Centre for Advancing Collaborative Healthcare and Education (CACHE) at the University Health Network and the University of Toronto.
Parker K, Binns A, Dupre C, Friesen F, Lising D, Sinclair L, Ng S. "What got you here, won't get you there": Students as leaders of the change we need. Healthc Manage Forum. 2024 Sep. DOI: 10.1177/08404704241259917.
*Recently, SLE’s have been renamed to Student Leadership Experiences. For more information visit the Centre for Advancing Collaborative Healthcare & Education website here.
Research conducted at UHN's research institutes spans the full spectrum of diseases and disciplines, including cancer, cardiovascular sciences, transplantation, neural and sensory sciences, musculoskeletal health, rehabilitation sciences, and community and population health.
Learn more about our institutes by clicking below:
